| Name | Opticare |
|---|---|
| Organization Name | Forks Optometric Ltd |
| Location | 421 Demers Ave, East Grand Forks, Minnesota 56721 |
| Type | Supplier |
| Phone | (218) 773-3438 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the second quarter and six months ended June 30, 2010. At June 30, 2010, Idenix's cash and cash equivalents totaled $51.0 million.
Marketing researchers at the University of Arkansas have completed a study of the impact of an anti-tobacco advertising campaign and found that attitudes toward the campaign and the campaign message were positively connected to the consideration among smokers to kick the habit.
Central to the study is FXO6, a peptide developed and patented by Austro-American company Fibrex Medical. Fibrex will now test the tolerability and pharmacokinetics of FX06 in humans. The peptide reduces inflammatory responses of the heart muscle that can arise after treatment for a myocardial infarction. Tests will begin immediately on the first - healthy - subjects at the Vienna General Hospital.
A delegation from the Alliance of Chinese-American Biotechnology and Pharmaceutical Associations (All-CABPA) visited Sundia in Shanghai's famous Zhangjiang Hi-Tech Park on October 12.
The August 8 visit of a U.S. delegation to the drought-stricken Horn of Africa "was important in terms of shedding light on the important efforts that are under way and the importance of continued support from the international community," Assistant Secretary of State for Population, Refugees and Migration Eric Schwartz said on Tuesday during a briefing on the trip, IIP Digital reports.
› Verified 8 days ago
News Archive
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the second quarter and six months ended June 30, 2010. At June 30, 2010, Idenix's cash and cash equivalents totaled $51.0 million.
Marketing researchers at the University of Arkansas have completed a study of the impact of an anti-tobacco advertising campaign and found that attitudes toward the campaign and the campaign message were positively connected to the consideration among smokers to kick the habit.
Central to the study is FXO6, a peptide developed and patented by Austro-American company Fibrex Medical. Fibrex will now test the tolerability and pharmacokinetics of FX06 in humans. The peptide reduces inflammatory responses of the heart muscle that can arise after treatment for a myocardial infarction. Tests will begin immediately on the first - healthy - subjects at the Vienna General Hospital.
A delegation from the Alliance of Chinese-American Biotechnology and Pharmaceutical Associations (All-CABPA) visited Sundia in Shanghai's famous Zhangjiang Hi-Tech Park on October 12.
The August 8 visit of a U.S. delegation to the drought-stricken Horn of Africa "was important in terms of shedding light on the important efforts that are under way and the importance of continued support from the international community," Assistant Secretary of State for Population, Refugees and Migration Eric Schwartz said on Tuesday during a briefing on the trip, IIP Digital reports.
› Verified 8 days ago
Opticare Type: Medicare Supplier Location: 421 Demers Ave, East Grand Forks, Minnesota 56721 Phone: (218) 773-3438 |